| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Practice Guidelines as Topic | 20 | 2024 | 1034 | 5.110 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 429 | 1.430 |
Why?
|
| Hypoglycemia | 1 | 2024 | 107 | 0.920 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 212 | 0.900 |
Why?
|
| Ambulatory Care | 1 | 2024 | 181 | 0.880 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 806 | 0.870 |
Why?
|
| Ferritins | 1 | 2021 | 29 | 0.820 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 19 | 0.820 |
Why?
|
| Humans | 61 | 2024 | 86601 | 0.780 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 91 | 0.760 |
Why?
|
| Macrolides | 1 | 2020 | 31 | 0.740 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 22 | 0.740 |
Why?
|
| beta-Lactams | 1 | 2020 | 14 | 0.740 |
Why?
|
| Smoking Cessation | 3 | 2016 | 230 | 0.730 |
Why?
|
| Smoking Prevention | 2 | 2016 | 43 | 0.730 |
Why?
|
| Lubricants | 1 | 2019 | 7 | 0.730 |
Why?
|
| Laxatives | 1 | 2019 | 13 | 0.720 |
Why?
|
| Testosterone | 2 | 2018 | 271 | 0.710 |
Why?
|
| Menorrhagia | 1 | 2020 | 24 | 0.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2018 | 1373 | 0.670 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2018 | 18 | 0.650 |
Why?
|
| Hair Removal | 1 | 2018 | 14 | 0.650 |
Why?
|
| Pneumonia | 1 | 2020 | 179 | 0.650 |
Why?
|
| Incidental Findings | 1 | 2018 | 95 | 0.640 |
Why?
|
| Hirsutism | 1 | 2018 | 61 | 0.640 |
Why?
|
| Algorithms | 2 | 2017 | 1830 | 0.640 |
Why?
|
| Hypogonadism | 1 | 2018 | 37 | 0.630 |
Why?
|
| Gender Dysphoria | 1 | 2017 | 6 | 0.630 |
Why?
|
| Mass Screening | 4 | 2015 | 617 | 0.620 |
Why?
|
| Aftercare | 1 | 2018 | 85 | 0.620 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 50 | 0.620 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 138 | 0.610 |
Why?
|
| Physician-Patient Relations | 4 | 2020 | 610 | 0.610 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 41 | 0.610 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 28 | 0.600 |
Why?
|
| Travel | 1 | 2017 | 68 | 0.600 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 144 | 0.600 |
Why?
|
| Organizations | 1 | 2017 | 17 | 0.600 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 162 | 0.580 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2600 | 0.570 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 239 | 0.570 |
Why?
|
| Diarrhea | 1 | 2017 | 182 | 0.570 |
Why?
|
| Thyroid Nodule | 1 | 2017 | 51 | 0.570 |
Why?
|
| Shock, Septic | 1 | 2017 | 102 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 378 | 0.550 |
Why?
|
| Behavior Therapy | 1 | 2016 | 75 | 0.540 |
Why?
|
| Health Services for the Aged | 1 | 2015 | 27 | 0.540 |
Why?
|
| Hepatitis C Antibodies | 1 | 2015 | 8 | 0.540 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 392 | 0.540 |
Why?
|
| Papillomavirus Vaccines | 2 | 2021 | 58 | 0.530 |
Why?
|
| Constipation | 1 | 2016 | 63 | 0.530 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 413 | 0.520 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 334 | 0.520 |
Why?
|
| Counseling | 1 | 2016 | 145 | 0.510 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 41 | 0.510 |
Why?
|
| Medication Adherence | 1 | 2016 | 129 | 0.510 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2017 | 192 | 0.510 |
Why?
|
| Residence Characteristics | 1 | 2016 | 197 | 0.500 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 206 | 0.500 |
Why?
|
| Quality Improvement | 3 | 2015 | 428 | 0.490 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 194 | 0.490 |
Why?
|
| Seizures | 1 | 2016 | 295 | 0.480 |
Why?
|
| Physicians | 2 | 2020 | 673 | 0.480 |
Why?
|
| Carotid Stenosis | 1 | 2015 | 112 | 0.470 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2015 | 112 | 0.470 |
Why?
|
| Recurrence | 1 | 2016 | 1139 | 0.470 |
Why?
|
| Adult | 18 | 2024 | 25640 | 0.460 |
Why?
|
| Sepsis | 1 | 2017 | 306 | 0.460 |
Why?
|
| Quality of Health Care | 3 | 2013 | 380 | 0.450 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 521 | 0.450 |
Why?
|
| Vaccination | 1 | 2014 | 254 | 0.440 |
Why?
|
| Hepatitis C | 1 | 2015 | 208 | 0.440 |
Why?
|
| Lung | 1 | 2018 | 1170 | 0.430 |
Why?
|
| Disease Management | 5 | 2019 | 327 | 0.430 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 408 | 0.420 |
Why?
|
| Extraterrestrial Environment | 1 | 2011 | 1 | 0.420 |
Why?
|
| Meteoroids | 1 | 2011 | 1 | 0.420 |
Why?
|
| Stars, Celestial | 1 | 2011 | 1 | 0.420 |
Why?
|
| Hypertension | 2 | 2017 | 1141 | 0.390 |
Why?
|
| Health Care Reform | 1 | 2011 | 90 | 0.350 |
Why?
|
| Stroke | 2 | 2018 | 965 | 0.350 |
Why?
|
| Female | 26 | 2021 | 44507 | 0.340 |
Why?
|
| United States | 8 | 2024 | 6665 | 0.310 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 827 | 0.310 |
Why?
|
| Health Maintenance Organizations | 3 | 1999 | 20 | 0.300 |
Why?
|
| Healthcare Disparities | 3 | 2010 | 370 | 0.300 |
Why?
|
| Attitude to Health | 2 | 1999 | 220 | 0.290 |
Why?
|
| Risk | 3 | 2024 | 674 | 0.280 |
Why?
|
| Male | 20 | 2021 | 40956 | 0.240 |
Why?
|
| Vaginal Smears | 2 | 2021 | 68 | 0.240 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 109 | 0.240 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 54 | 0.240 |
Why?
|
| Aortic Diseases | 1 | 2024 | 100 | 0.230 |
Why?
|
| Sex Factors | 4 | 2021 | 1054 | 0.220 |
Why?
|
| Coronary Artery Disease | 3 | 2013 | 350 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 166 | 0.220 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2021 | 5 | 0.210 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2261 | 0.210 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2016 | 45 | 0.210 |
Why?
|
| Middle Aged | 15 | 2020 | 25017 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 864 | 0.200 |
Why?
|
| Gout Suppressants | 1 | 2021 | 36 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 38 | 0.200 |
Why?
|
| Physicians, Primary Care | 3 | 2012 | 104 | 0.200 |
Why?
|
| Postmenopause | 1 | 2021 | 98 | 0.200 |
Why?
|
| Gout | 1 | 2021 | 76 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2018 | 2261 | 0.200 |
Why?
|
| Iron | 1 | 2021 | 164 | 0.190 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 106 | 0.190 |
Why?
|
| Smoking | 2 | 2015 | 609 | 0.190 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2021 | 153 | 0.190 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2020 | 8 | 0.180 |
Why?
|
| Morphinans | 1 | 2019 | 4 | 0.180 |
Why?
|
| Uterine Diseases | 1 | 2020 | 19 | 0.180 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 48 | 0.180 |
Why?
|
| Bone Marrow | 1 | 2021 | 435 | 0.180 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 71 | 0.180 |
Why?
|
| Acute Disease | 2 | 2021 | 826 | 0.180 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 63 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 275 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 36 | 0.170 |
Why?
|
| Guideline Adherence | 3 | 2021 | 223 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 378 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 243 | 0.160 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2018 | 31 | 0.160 |
Why?
|
| Urban Health Services | 2 | 2011 | 45 | 0.160 |
Why?
|
| Naltrexone | 1 | 2019 | 135 | 0.160 |
Why?
|
| Premenopause | 1 | 2018 | 54 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 154 | 0.160 |
Why?
|
| Pregnancy | 2 | 2016 | 2893 | 0.160 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2018 | 147 | 0.160 |
Why?
|
| Informed Consent By Minors | 1 | 2017 | 2 | 0.160 |
Why?
|
| Luteinizing Hormone | 1 | 2018 | 167 | 0.160 |
Why?
|
| Sex Reassignment Procedures | 1 | 2017 | 4 | 0.160 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 45 | 0.160 |
Why?
|
| Antidiarrheals | 1 | 2017 | 14 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 141 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 894 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2018 | 109 | 0.150 |
Why?
|
| Mental Competency | 1 | 2017 | 49 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 363 | 0.150 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 103 | 0.150 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 193 | 0.150 |
Why?
|
| Weight Loss | 1 | 2018 | 229 | 0.150 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 1990 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 48 | 0.150 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 34 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2018 | 272 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 81 | 0.140 |
Why?
|
| Social Perception | 1 | 1997 | 95 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 297 | 0.140 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2018 | 203 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2017 | 155 | 0.130 |
Why?
|
| Age Factors | 6 | 2021 | 1849 | 0.130 |
Why?
|
| Physician's Role | 1 | 1997 | 179 | 0.130 |
Why?
|
| Cause of Death | 1 | 2016 | 277 | 0.130 |
Why?
|
| Aged | 9 | 2016 | 18402 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 434 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2017 | 326 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2018 | 873 | 0.120 |
Why?
|
| Pressure Ulcer | 2 | 2013 | 42 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2014 | 86 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2014 | 90 | 0.120 |
Why?
|
| Documentation | 2 | 2013 | 98 | 0.120 |
Why?
|
| Aging | 1 | 1999 | 691 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2015 | 159 | 0.120 |
Why?
|
| Critical Care | 1 | 2017 | 370 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1565 | 0.120 |
Why?
|
| Hospitalization | 3 | 2016 | 848 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2013 | 66 | 0.110 |
Why?
|
| Teaching | 2 | 2011 | 147 | 0.110 |
Why?
|
| Checklist | 1 | 2013 | 57 | 0.110 |
Why?
|
| Epilepsy | 1 | 2016 | 395 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2015 | 695 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 746 | 0.110 |
Why?
|
| Carbon Compounds, Inorganic | 1 | 2011 | 1 | 0.110 |
Why?
|
| Silicon Compounds | 1 | 2011 | 1 | 0.110 |
Why?
|
| Communication | 2 | 2019 | 440 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2016 | 535 | 0.110 |
Why?
|
| Diamond | 1 | 2011 | 3 | 0.110 |
Why?
|
| Nitrogen Isotopes | 1 | 2011 | 14 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 1143 | 0.110 |
Why?
|
| Graphite | 1 | 2011 | 12 | 0.100 |
Why?
|
| Carbon Isotopes | 1 | 2011 | 76 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2016 | 572 | 0.100 |
Why?
|
| Education | 1 | 2011 | 58 | 0.100 |
Why?
|
| Primary Health Care | 3 | 2011 | 339 | 0.100 |
Why?
|
| Patients | 1 | 2012 | 100 | 0.100 |
Why?
|
| Models, Chemical | 1 | 2011 | 178 | 0.100 |
Why?
|
| Patient Handoff | 1 | 2012 | 93 | 0.100 |
Why?
|
| Medical Informatics Applications | 1 | 2010 | 9 | 0.100 |
Why?
|
| Risk Factors | 3 | 2016 | 5416 | 0.090 |
Why?
|
| Patient Transfer | 1 | 2011 | 91 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2011 | 150 | 0.090 |
Why?
|
| Awareness | 1 | 2010 | 93 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2011 | 160 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 169 | 0.090 |
Why?
|
| Sigmoidoscopy | 1 | 1989 | 36 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 62 | 0.090 |
Why?
|
| Minority Groups | 2 | 2007 | 137 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 169 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 207 | 0.080 |
Why?
|
| Albuminuria | 1 | 2010 | 153 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2016 | 8475 | 0.080 |
Why?
|
| Hospitalists | 1 | 2010 | 131 | 0.080 |
Why?
|
| Inpatients | 1 | 2011 | 297 | 0.080 |
Why?
|
| Mandatory Reporting | 1 | 2007 | 7 | 0.080 |
Why?
|
| Adolescent | 2 | 2017 | 8979 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2010 | 300 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 37 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 240 | 0.070 |
Why?
|
| Program Development | 1 | 2007 | 124 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2207 | 0.070 |
Why?
|
| Hospitals, Teaching | 3 | 2011 | 115 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 220 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2006 | 85 | 0.070 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 129 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2021 | 373 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2016 | 4210 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6501 | 0.060 |
Why?
|
| Analgesics | 2 | 2021 | 119 | 0.060 |
Why?
|
| American Heart Association | 1 | 2024 | 92 | 0.060 |
Why?
|
| Age of Onset | 1 | 2024 | 310 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2012 | 1004 | 0.060 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2021 | 6 | 0.050 |
Why?
|
| Uricosuric Agents | 1 | 2021 | 11 | 0.050 |
Why?
|
| American Cancer Society | 1 | 2021 | 13 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 5209 | 0.050 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 27 | 0.050 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 20 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 53 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 1989 | 938 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2021 | 167 | 0.050 |
Why?
|
| Uric Acid | 1 | 2021 | 139 | 0.050 |
Why?
|
| Chicago | 3 | 1997 | 1379 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 999 | 0.050 |
Why?
|
| Logistic Models | 2 | 2011 | 1185 | 0.050 |
Why?
|
| Manipulation, Orthopedic | 1 | 1999 | 5 | 0.050 |
Why?
|
| Low Back Pain | 1 | 1999 | 40 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Plants, Toxic | 1 | 1999 | 26 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 294 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2013 | 319 | 0.040 |
Why?
|
| Liver | 1 | 2023 | 1229 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 97 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 141 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 38 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2024 | 7988 | 0.040 |
Why?
|
| Self Disclosure | 1 | 1997 | 31 | 0.040 |
Why?
|
| Research | 1 | 2019 | 253 | 0.040 |
Why?
|
| Personality Inventory | 1 | 1997 | 108 | 0.040 |
Why?
|
| Health Promotion | 1 | 1999 | 160 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1576 | 0.040 |
Why?
|
| New Zealand | 1 | 2016 | 22 | 0.040 |
Why?
|
| Health Personnel | 1 | 1999 | 202 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 364 | 0.040 |
Why?
|
| Australia | 1 | 2016 | 99 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 1997 | 278 | 0.040 |
Why?
|
| Mental Recall | 1 | 1997 | 159 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 116 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 204 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 912 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 395 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 478 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cognition | 1 | 1997 | 570 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 454 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 1239 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2013 | 232 | 0.030 |
Why?
|
| Global Health | 1 | 2013 | 193 | 0.030 |
Why?
|
| Videoconferencing | 1 | 2011 | 16 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 1997 | 1621 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2011 | 47 | 0.030 |
Why?
|
| Models, Educational | 1 | 2011 | 50 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 144 | 0.030 |
Why?
|
| Bedding and Linens | 1 | 2011 | 12 | 0.020 |
Why?
|
| Personnel, Hospital | 1 | 2011 | 30 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 860 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 857 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 54 | 0.020 |
Why?
|
| Patient Preference | 1 | 2011 | 105 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 59 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2378 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 229 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 243 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2010 | 71 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3045 | 0.020 |
Why?
|
| Patient Participation | 1 | 2011 | 216 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 596 | 0.020 |
Why?
|
| Perception | 1 | 2010 | 168 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2010 | 256 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3611 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 327 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2012 | 347 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 839 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2501 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2011 | 265 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1989 | 297 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 678 | 0.020 |
Why?
|
| Data Collection | 1 | 1989 | 372 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2270 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1989 | 451 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 319 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3636 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2011 | 751 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2767 | 0.020 |
Why?
|
| Child | 1 | 2016 | 6926 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 556 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2006 | 261 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 25 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5974 | 0.020 |
Why?
|
| Ventricular Dysfunction | 1 | 2004 | 28 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 2887 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 3674 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 318 | 0.010 |
Why?
|
| Medicare | 1 | 2006 | 406 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 751 | 0.010 |
Why?
|
| Manipulation, Spinal | 1 | 1999 | 2 | 0.010 |
Why?
|
| Physical Therapy Modalities | 1 | 1999 | 84 | 0.010 |
Why?
|
| Echocardiography | 1 | 2004 | 911 | 0.010 |
Why?
|
| Mammography | 1 | 1997 | 461 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 2705 | 0.010 |
Why?
|